Alira Health

Essential Elements of Technology Transfer

The lifecycle of pharmaceutical development always requires the transfer of the production process and analytical methods from development into Good Manufacturing Practices (GMP) manufacturing and quality control laboratories.

This transfer can take many forms. Traditional pharmaceutical organizations usually have full in-house product development and manufacturing capability, whereas small startup organizations leverage contract development and manufacturing organizations (CDMOs) to bring their discoveries from the research bench to human clinical trials.

Regardless of the nature and maturity of the organization, an effective technology transfer program is essential to the success of pharmaceutical development.

Scientific Articles
Category:
Published on:
September 21, 2023
Peter Alexander

Our own Peter Alexander, Senior Consultant, Chemistry, Manufacturing & Controls (CMC), co-authored an article entitled “Essential Elements Of Technology Transfer” that dives into technology transfer categories, essential elements, documentation, and much more.

The article is available on “Bioprocess Online.”

Contact us to discover how our team’s comprehensive knowledge in biologics and ADCs can make a significant difference in your development journey.

Related news

Reports and White Papers September 1, 2026
Global Medtech Contract Development and Manufacturing Market H1 2026 M&A Update
Learn about the H1 2026 M&A trends in the medtech CDMO market including deal activity, geographic distribution of transactions, and target end-markets.
CDMO MedTech
News July 22, 2026
Specialized Manufacturing Capability Emerges as the New Competitive Advantage in the $23.2 Billion Global Biologics CDMO Market, Finds Alira Health
Alira Health, a global healthcare consultancy, today released the 2026 Biologics Contract Manufacturing Report, its annual analysis of the global contract development and manufacturing(...)
Biologics CDMO Contract Manufacturing
Reports and White Papers July 21, 2026
The 2026 Biologics Contract Manufacturing Report
Discover the latest biologics CDMO market insights on manufacturing, investment, and M&A trends shaping the industry. Access the 2026 report today.
Advanced Therapies Biologics CDMO
Articles May 15, 2026
Four Capabilities Redefining Competitive Advantage in Biologics CDMOs in 2026
Learn how biologics CDMO leaders strengthen competitive advantage in 2026 with resilient networks, AI-driven execution, and disciplined capital strategies.
Biologics CDMO
Reports and White Papers March 30, 2026
The 2026 Global Medtech Contract Development and Manufacturing Report
Download this free report now to access the key trends shaping outsourcing strategies, deal activity, and capability development across the industry in 2026.
CDMO MedTech
Events March 23, 2026
TIDES USA 2026
Meet Alira Health’s CMC experts onsite to discuss your product development challenges and CDMO selection needs.
CMC USA
Reports and White Papers March 20, 2026
2026 Biologics CDMO Public Market Update
Access public biologics CDMO valuation trends, global competitive dynamics, IPO and equity market signals, investment flows, and capacity expansion outlook.
Biologics CDMO
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.